Prelude Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
PRLD$3.760.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss (Unaudited)
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands, except share and per share data) | 2024 | 2023 |
| Operating expenses: | ||
| Research and development | $27,409 | $21,834 |
| General and administrative | 6,934 | 7,281 |
| Total operating expenses | 34,343 | 29,115 |
| Loss from operations | (34,343) | (29,115) |
| Other income, net | 2,912 | 1,397 |
| Net loss | $(31,431) | $(27,718) |
| Per share information: | ||
| Net loss per share of common stock, basic and diluted | $(0.42) | $(0.58) |
| Weighted average common shares outstanding, basic and diluted | 75,735,954 | 47,737,190 |
| Comprehensive loss: | ||
| Net loss | $(31,431) | $(27,718) |
| Unrealized (loss) gain on marketable securities, net of tax | (458) | 1,294 |
| Comprehensive loss | $(31,889) | $(26,424) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.